These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 26316621

  • 1. Eculizumab in Pediatric Dense Deposit Disease.
    Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1773-82. PubMed ID: 26316621
    [Abstract] [Full Text] [Related]

  • 2. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G, EAGLE Study Group.
    Am J Kidney Dis; 2019 Aug 07; 74(2):224-238. PubMed ID: 30929851
    [Abstract] [Full Text] [Related]

  • 3. Eculizumab for dense deposit disease and C3 glomerulonephritis.
    Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB.
    Clin J Am Soc Nephrol; 2012 May 07; 7(5):748-56. PubMed ID: 22403278
    [Abstract] [Full Text] [Related]

  • 4. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
    Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, Daugas E, Decramer S, Tricot L, Cailliez M, Dubot P, Servais A, Mourey-Epron C, Pourcine F, Loirat C, Frémeaux-Bacchi V, Fakhouri F.
    Am J Kidney Dis; 2018 Jul 07; 72(1):84-92. PubMed ID: 29429752
    [Abstract] [Full Text] [Related]

  • 5. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
    Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.
    Pediatr Nephrol; 2014 Jun 07; 29(6):1107-11. PubMed ID: 24408225
    [Abstract] [Full Text] [Related]

  • 6. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
    Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC.
    Pediatr Nephrol; 2016 Apr 07; 31(4):683-7. PubMed ID: 26759144
    [Abstract] [Full Text] [Related]

  • 7. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 8. Eculizumab for the treatment of dense-deposit disease.
    Vivarelli M, Pasini A, Emma F.
    N Engl J Med; 2012 Mar 22; 366(12):1163-5. PubMed ID: 22435383
    [No Abstract] [Full Text] [Related]

  • 9. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
    Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL.
    Pediatr Nephrol; 2017 Jun 22; 32(6):1023-1028. PubMed ID: 28236143
    [Abstract] [Full Text] [Related]

  • 10. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K, Martola L, Räisänen-Sokolowski A, Meri S.
    Clin Immunol; 2018 Feb 22; 187():104-106. PubMed ID: 29097196
    [Abstract] [Full Text] [Related]

  • 11. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
    Ozkaya O, Nalcacioglu H, Tekcan D, Genc G, Meydan BC, Ozdemir BH, Baysal MK, Keceligil HT.
    Pediatr Nephrol; 2014 Jul 22; 29(7):1283-7. PubMed ID: 24464478
    [Abstract] [Full Text] [Related]

  • 12. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients.
    Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD.
    Clin J Am Soc Nephrol; 2009 Jan 22; 4(1):22-32. PubMed ID: 18971369
    [Abstract] [Full Text] [Related]

  • 13. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A, Tallón S, Hernández-Sevillano B, de Arriba G.
    Rev Clin Esp (Barc); 2014 Jan 22; 214(5):266-74. PubMed ID: 24576419
    [Abstract] [Full Text] [Related]

  • 14. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C, Podestà MA, Abbate M, Rizzo P, Piras R, Alberti M, Daina E, Ruggenenti P, Remuzzi G, on behalf of the EAGLE Study Group.
    Nephron; 2020 Jan 22; 144(4):195-203. PubMed ID: 32050203
    [Abstract] [Full Text] [Related]

  • 15. Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?
    Duineveld C, Steenbergen EJ, Bomback AS, van de Kar NCAJ, Wetzels JFM.
    Pediatr Nephrol; 2020 Sep 22; 35(9):1791-1795. PubMed ID: 32447506
    [Abstract] [Full Text] [Related]

  • 16. Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study.
    Welte T, Arnold F, Westermann L, Rottmann FA, Hug MJ, Neumann-Haefelin E, Ganner A.
    BMC Nephrol; 2023 Jan 11; 24(1):8. PubMed ID: 36631797
    [Abstract] [Full Text] [Related]

  • 17. Anti-complement therapy for glomerular diseases.
    Bomback AS.
    Adv Chronic Kidney Dis; 2014 Mar 11; 21(2):152-8. PubMed ID: 24602464
    [Abstract] [Full Text] [Related]

  • 18. Eculizumab in dense-deposit disease after renal transplantation.
    Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, Rodríguez de Córdoba S, Ybot-González P.
    Pediatr Nephrol; 2014 Oct 11; 29(10):2055-9. PubMed ID: 24908321
    [Abstract] [Full Text] [Related]

  • 19. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C, Horinouchi T, Inoki Y, Ichikawa Y, Tanaka Y, Kitakado H, Kondo A, Sakakibara N, Nagano C, Yamamura T, Fujimura J, Kamiyoshi N, Ishimori S, Ninchoji T, Kaito H, Shima Y, Iijima K, Nozu K, Yoshikawa N.
    Pediatr Nephrol; 2024 Sep 11; 39(9):2679-2689. PubMed ID: 38662234
    [Abstract] [Full Text] [Related]

  • 20. A case of C3 glomerulonephritis successfully treated with eculizumab.
    Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL.
    Pediatr Nephrol; 2015 Jun 11; 30(6):1033-7. PubMed ID: 25796589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.